Dermatology
News, opinions and meeting coverage in dermatology.
— 38% of patients treated with IL-13 blocker achieved clear or almost-clear skin at 16 weeks
Latest in Dermatology
Parents and child psychologists worry about the trend's effects on girls' mental health
However, this benefit was lost if smoking was resumed
A 55-year-old man visited his doctor for a growth that developed on his right leg, at the site of previous surgery, 2 months prior. Can you diagnose the patient?
More data for discussion of controversial association between steroids, immunotherapy
A 55-year-old man visited his doctor for a growth that developed on his right leg, at the site of previous surgery, 2 months prior. Can you diagnose the patient?
More data for discussion of controversial association between steroids, immunotherapy
Dermatology Case Studies
Long-ignored patches of progressively hardening skin finally receive a rare diagnosis
Treatment-resistant juvenile dermatomyositis resolved by targeting elevated interferon-beta
Incision sites were itchy, painful, red, and oozing and were not showing signs of healing
More in Dermatology
Also in TTHealthWatch: computer interfaces for communication in people with ALS
Long-term maintenance therapy is necessary, researchers caution
Nemolizumab significantly improved itch, nodules, and sleep disturbance at 16 weeks
Early recurrence after anti-PD-1/L1 likely to benefit more from anti-CTLA-4, targeted agents
Sulfonamides and cephalosporins the worst offenders, study finds
New iteration of denileukin diftitox led to objective responses in 36% of pretreated patients
More than 90% of patients met response criteria at 68 weeks with 8- or 16-week dosing
Consumers should see a dermatology professional when it comes to these products, she says
This could exacerbate disease burden and reduce quality of life, researchers say
Over 30% of patients had at least 80% scalp hair regrowth with deuruxolitinib
Low-dose treatment appeared effective in patients taking meds for various comorbidities
Blackness, per se, seen as less important than area socioeconomics
More patients see treatment success with delgocitinib vs cream vehicle in two phase III trials
